FACT-CHECKED AGAINST PEER-REVIEWED LITERATURE | Sources include PubMed/NCBI, Drug Testing and Analysis, and the journal Human Psychopharmacology. Full citations in References section.
What is 1P-LSD? Chemistry, Effects, Legality, and How It Compares to LSD
When 1P-LSD first appeared on online research chemical markets in early 2015, most people assumed it was a legal loophole product — something designed to look like LSD on paper without actually being it. Nearly a decade of scientific investigation has complicated that picture considerably. What researchers have found is that 1P-LSD is not simply a legal imitation. It is, pharmacologically speaking, a prodrug of LSD — a compound that the human body converts into LSD itself. Understanding what that means, and what it doesn’t, is the starting point for any honest discussion of this substance.
What is 1P-LSD? The Chemistry Explained
1P-LSD stands for 1-propionyl-lysergic acid diethylamide. It is a semi-synthetic compound belonging to the lysergamide family — the same chemical family that includes LSD, ALD-52 (also called 1A-LSD), 1B-LSD, 1D-LSD, and 1S-LSD, among others. The structural difference between 1P-LSD and LSD is the addition of a propionyl group — a three-carbon acyl chain — attached to the nitrogen atom of LSD’s indole group at the N-1 position.
That single modification is what gives 1P-LSD its name, its legal distinctiveness in certain jurisdictions, and its pharmacological character. The compound was first analytically characterized in a 2015 study published in Human Psychopharmacology by Brandt et al. — the first time it had appeared in peer-reviewed scientific literature, despite already being available for purchase online. Lizard Labs, a Netherlands-based research chemical laboratory, is generally credited with its initial synthesis and commercial introduction.
Is 1P-LSD a Prodrug of LSD?
The short answer is yes, with strong supporting evidence. A 2020 study published in Drug Testing and Analysis by Brandt, Kavanagh, Dowling, Talbot, and colleagues administered 1P-LSD to human volunteers via both oral and intravenous routes and analyzed blood and urine samples over time. The findings were clear: 1P-LSD was detectable in serum for only about 4 hours, while LSD was detected in all serum samples after 24 hours and in urine for up to 80 hours post-administration. The bioavailability of LSD following 1P-LSD administration was close to 100%.
In plain terms: when you take 1P-LSD, your body — specifically liver enzymes — cleaves the propionyl group from the molecule, leaving behind LSD. The 1P-LSD itself is pharmacologically inert or near-inert. The effects you experience are the effects of LSD. This is why the 2015 animal study by the same research group found that 1P-LSD produced dose-dependent LSD-like head-twitch responses in mice — a well-validated behavioral marker of 5-HT2A receptor activation — and that these responses were abolished by the selective 5-HT2A receptor antagonist M100907, confirming serotonergic mediation.
Prominent psychedelic pharmacologist David E. Nichols has also noted that the propionyl group would prevent 1P-LSD from fitting properly into the 5-HT2A receptor binding site, further supporting the prodrug interpretation — the compound must shed that group before it can act on the receptor.
1P-LSD Effects: What Does the Science Say?
Because 1P-LSD is a prodrug of LSD, its effects are functionally those of LSD — just delayed slightly by the time needed for metabolic conversion. The pharmacokinetic profile documented in the 2020 human study shows:
- Onset: approximately 20 to 60 minutes after oral administration
- Peak effects: 2 to 4 hours post-dose
- Duration: 8 to 12 hours for most users
- Typical dose range: 100 to 200 micrograms (µg), with 150 µg considered a standard dose
Subjectively, users report effects consistent with LSD: visual phenomena including geometric patterns and enhanced color perception, altered time perception, synesthesia, emotional amplification, increased introspection, and changes in thought patterns. The 2020 human study used visual analog scales to compare the qualitative effects of 1P-LSD and LSD and found them to be similar — though it was a small-scale study and not a powered comparative trial.
Does 1P-LSD Feel Different from LSD?
Anecdotal reports from the psychonaut community — the primary source of human experiential data given the limited clinical research — consistently describe 1P-LSD as virtually indistinguishable from LSD in terms of qualitative effects. Some users note a marginally slower onset, which the prodrug mechanism explains: the body needs time to complete metabolic conversion before LSD levels in the bloodstream rise significantly. A small subset of users report the experience feeling slightly softer in the early stages, again consistent with the conversion kinetics.
No controlled human trial has yet formally compared the subjective experience of 1P-LSD and LSD in a powered, blinded study. That gap in the literature is important to acknowledge — the pharmacokinetic equivalence is well-established, but the phenomenological equivalence rests primarily on the 2020 analog scale data and observational reports.
The Lysergamide Family: 1P-LSD, 1D-LSD, and 1S-LSD
1P-LSD belongs to a broader family of LSD analogs that emerged primarily as regulatory responses to tightening drug laws. Understanding where it sits in this family helps clarify the landscape:
- 1P-LSD (1-propionyl-LSD): The original and most studied member of the modern lysergamide analog series. Propionyl group (3-carbon chain) at N-1 position. Prodrug of LSD with near-complete conversion documented in humans.
- 1D-LSD (1-dimethylsulfamoyl-LSD): A later generation analog developed after 1P-LSD faced legislative controls in Germany under the NpSG (New Psychoactive Substances Act). Banned in Germany in June 2024 under updated NpSG scheduling.
- 1S-LSD (1-(3-(trimethylsilyl)propionyl)-LSD): The most recent major analog, introduced in Germany in September 2024 specifically to circumvent the NpSG controls that caught 1D-LSD. The trimethylsilyl group was chosen because it falls outside current NpSG regulatory coverage. As of August 2024, 1S-LSD remains legal in Germany for this reason.
This pattern — a new analog introduced each time legislation closes the door on the previous one — is sometimes called the cat-and-mouse cycle of novel psychoactive substance regulation. It reflects a fundamental tension in drug policy: chemical modification is faster than legislative response, and each new compound arrives with even less clinical safety data than the last.
1P-LSD Legal Status: A Country-by-Country Reality
The legal status of 1P-LSD varies significantly by jurisdiction and changes frequently. This is a general overview based on the best available information at time of writing — always verify current local law before drawing conclusions:
- United States: Not explicitly scheduled as 1P-LSD at the federal level. However, the Federal Analogue Act (FAA) classifies substances substantially similar to Schedule I or II compounds as Schedule I equivalents if intended for human consumption. Most vendors sell 1P-LSD labeled as ‘not for human consumption’ to navigate this provision — but that label does not eliminate legal risk, and enforcement can occur.
- United Kingdom: Controlled under the Psychoactive Substances Act 2016. Production, supply, and importation are criminal offenses regardless of whether it is explicitly scheduled by name.
- Germany: Initially uncontrolled, then brought under the NpSG. 1P-LSD itself is now scheduled under Germany’s NpSG, which prompted the development of 1D-LSD and subsequently 1S-LSD.
- Australia and Japan: Covered under broad analog bans that capture LSD analogs regardless of specific naming.
- Canada: Not a controlled substance as of 2025, though analog provisions may apply depending on context.
The consistent regulatory trend globally is toward tightening. Any jurisdiction that has not yet explicitly scheduled 1P-LSD is likely to do so as awareness grows. Treating 1P-LSD as legally safe anywhere without current, jurisdiction-specific legal advice is an error with real consequences.
Safety Profile and Harm Reduction
The honest answer on 1P-LSD safety is that formal long-term data does not exist. Given its prodrug status, it is reasonable to assume it shares the general safety profile of LSD — a substance with a well-documented, relatively favorable physiological risk profile at recreational doses. But ‘reasonable to assume’ is not the same as ‘confirmed by clinical research,’ and that distinction matters.
What the available evidence suggests:
- No formal studies have documented direct toxicity from 1P-LSD at standard doses in human subjects
- Addiction potential is presumed low, consistent with LSD — animal models have not shown self-administration behavior
- Tolerance develops rapidly, consistent with LSD’s 5-HT2A receptor downregulation mechanism, and cross-tolerance with other classic psychedelics including psilocybin and mescaline is expected
- Psychological risks mirror those of LSD: difficult experiences, anxiety, and in rare cases psychological crisis — particularly in individuals with personal or family history of psychotic disorders
- Drug substitution risk: as with LSD, substances sold as 1P-LSD may be adulterated or misrepresented; Ehrlich reagent testing does not distinguish 1P-LSD from LSD, but will distinguish both from non-indole compounds like NBOMe analogs
Conclusion & Actionable Takeaways
1P-LSD is not a mystery substance or a dramatically different drug from LSD. The pharmacological evidence is clear: it is a prodrug that the human body converts to LSD, producing effects functionally equivalent to LSD with a marginally delayed onset. Understanding it in that context — rather than treating it as either entirely safe because of its research chemical label, or dismissing it as identical to LSD in every legal sense — is the starting point for informed decision-making.
- 1P-LSD is a prodrug of LSD — the 2020 human pharmacokinetic study confirmed near-complete metabolic conversion, meaning the active compound in your body is LSD
- Effects are functionally equivalent to LSD: onset 20-60 minutes, peak at 2-4 hours, duration 8-12 hours, standard dose 100-200 µg
- The lysergamide family — 1P-LSD, 1D-LSD, 1S-LSD — represents a regulatory cat-and-mouse cycle; each compound carries less safety data than the last
- Legal status varies dramatically by country and is tightening globally — the Federal Analogue Act in the US creates enforcement risk even without explicit scheduling
- Safety profile is presumed similar to LSD given the prodrug mechanism, but long-term formal safety data does not exist — this is not a substitute for clinical confirmation
- Psychological risk factors that apply to LSD apply equally here: avoid use if you have a personal or family history of psychotic disorders
- Always use an Ehrlich reagent test on any substance sold as 1P-LSD — a negative result (no purple color) indicates absence of indole alkaloids and is a red flag
- The research chemical label and ‘not for human consumption’ packaging do not confer legal protection in jurisdictions with analog laws — understand your local legal risk before acting
References
All factual claims in this article are grounded in the following peer-reviewed studies and authoritative sources:
4. Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin Pharmacokinet. 2017 Oct;56(10):1219-1230. doi: 10.1007/s40262-017-0513-9. PMID: 28197931.
5. Nichols DE. Psychedelics. Pharmacol Rev. 2016 Apr;68(2):264-355. doi: 10.1124/pr.115.011478. PMID: 26841948.
8. Wikipedia contributors. 1S-LSD. Wikipedia, The Free Encyclopedia; 2024. Available from: https://en.wikipedia.org/wiki/1S-LSD
9. United States Drug Enforcement Administration. Federal Analogue Act, 21 U.S.C. § 813. Available from: https://www.dea.gov
10. United Kingdom Home Office. Psychoactive Substances Act 2016. Available from: https://www.legislation.gov.uk/ukpga/2016/2/contents/enacted
Disclaimer: This article is intended for educational and informational purposes only. It does not constitute legal or medical advice. The legal status of 1P-LSD, 1D-LSD, and 1S-LSD varies by jurisdiction and changes frequently. Always verify current local law before drawing any conclusions. If you are struggling with substance use, SAMHSA’s National Helpline is available 24/7 at 1-800-662-4357.